Tau Thr217 phosphorylation
Tau Thr217 phosphorylation
Recent research has identified increased Tau Thr217 phosphorylation as a significant biomarker in Alzheimer’s disease (AD). Elevated levels of Tau Thr217 phosphorylation have been detected in both cerebrospinal fluid (CSF) and blood plasma during the early stages of AD, distinguishing patients with AD from those with other neurodegenerative disorders and healthy individuals. A novel immunoassay targeting Tau Thr217 phosphorylation demonstrated 90% accuracy in identifying AD patients, outperforming assays for other tau phosphorylation sites.
The cellular localization of Tau Thr217 phosphorylation in the brain further underscores its relevance to AD pathology. Immunostaining of postmortem AD brain tissue revealed that Tau Thr217 phosphorylation is present in neurofibrillary tangles and neuropil threads, structures commonly associated with AD. Notably, Tau Thr217 phosphorylation was also found in vesicular structures linked to granulovacuolar degeneration bodies and multivesicular bodies, suggesting a unique role in the disease process. Individuals with a high likelihood of AD exhibited significantly higher Tau Thr217 phosphorylation area fractions in various brain regions compared to those with primary age-related tauopathy or other non-AD tauopathies.
The relationship between amyloid-beta (Aβ) pathology and tau hyperphosphorylation is well-documented, with Aβ accumulation promoting tau phosphorylation. Glycogen synthase kinase-3 beta (GSK-3β), a kinase implicated in tau phosphorylation, directly phosphorylates tau at Thr217. This process is further accelerated by Aβ, leading to increased Tau Thr217 phosphorylation levels. Studies have shown that mutations mimicking phosphorylation at Thr217 enhance tau fibrillization, contributing to neurofibrillary tangle formation, a hallmark of AD.
